Understand the source comparison
Selective Androgen Receptor Modulators vs Growth Hormone Pathways
Selective androgen receptor modulators (SARMs) and growth hormone secretagogues are often conflated in research discussions, but their mechanisms are fundamentally different. SARMs bind androgen receptors directly. Mimicking testosterone's anabolic effects in
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Selective androgen receptor modulators (SARMs) and growth hormone secretagogues are often conflated in research discussions, but their mechanisms are fundamentally different. SARMs bind androgen receptors directly. Mimicking testosterone's anabolic effects in muscle and bone tissue while theoretically sparing prostate and cardiovascular tissue. Growth hormone secretagogues, by contrast, do not bind androgen receptors at all. They modulate the HPG axis upstream, which allows the body to produce its own testosterone rather than replacing it exogenously.
- The practical implication for research: SARMs suppress endogenous testosterone production through negative feedback on the hypothalamus and pituitary, just as exogenous testosterone does. Even tissue-selective SARMs like ostarine (enobosarm) demonstrated LH suppression of 40–55% at 3mg daily in Phase II trials, with total testosterone declining by 23% from baseline. Recovery post-cessation took 4–8 weeks. Growth hormone secretagogues, conversely, do not suppress the HPG axis. They restore it. This makes them mechanistically distinct tools for research focused on endogenous androgen pathway function rather than exogenous receptor activation.
- MK-677 (ibutamoren) occupies a middle ground. It's a ghrelin receptor agonist like ipamorelin but with a much longer half-life (24 hours) and oral bioavailability, which makes it structurally closer to a small-molecule drug than a peptide. Research published in Journal of Clinical Endocrinology & Metabolism found that MK-677 at 25mg daily increased mean 24-hour GH secretion by 97% and IGF-1 levels by 60–90%, sustained across 12 months of continuous dosing. The testosterone effects were secondary: in older adults, free testosterone increased by 11–14% at 6 months, likely due to improved LH pulsatility. Unlike short-acting peptides, MK-677 provides sustained GH elevation without injection. But also without the pulsatile pattern that mimics natural GH secretion, which some researchers consider a mechanistic trade-off.
- Here's what researchers miss: the pulsatile pattern of GH release matters more than absolute GH levels for HPG axis modulation. The hypothalamus responds to peaks and troughs in GH signalling, not steady-state elevation. CJC-1295 with DAC and ipamorelin preserve pulsatility because they amplify endogenous secretion bursts rather than flattening them into continuous release. MK-677, by contrast, produces steady-state GH elevation. Which is metabolically beneficial but may not optimally stimulate the feedback mechanisms that govern LH secretion. For research specifically targeting testosterone pathway restoration, pulsatile secretagogues like ipamorelin may offer mechanistic advantages over continuous ghrelin agonists.
- The peptide combinations we've seen produce the most consistent HPG axis modulation in published research pair a GHRH analogue (CJC-1295) with a ghrelin mimetic (ipamorelin or GHRP-2). This dual-action approach activates both GHRH receptors and GHS-R1a receptors simultaneously, producing synergistic GH release that exceeds either peptide administered alone. A study in Growth Hormone & IGF Research demonstrated that CJC-1295 plus ipamorelin co-administration produced GH peak elevations 40% higher than the sum of their individual effects. Suggesting receptor pathway complementarity rather than simple additive action.